A detailed history of Gables Capital Management Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Gables Capital Management Inc. holds 121 shares of VRTX stock, worth $54,598. This represents 0.03% of its overall portfolio holdings.

Number of Shares
121
Previous 121 -0.0%
Holding current value
$54,598
Previous $56,000 -0.0%
% of portfolio
0.03%
Previous 0.03%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 07, 2020

BUY
$199.77 - $247.81 $24,172 - $29,985
121 New
121 $29,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Gables Capital Management Inc. Portfolio

Follow Gables Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gables Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Gables Capital Management Inc. with notifications on news.